Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824027 | 0.82 | NPC1 (0.54) | HTTALDH1A1TSHRTAS1R3TAS1R1 | |
| SCHEMBL5121647 | 0.81 | HTT (0.53) | HTTALDH1A1TSHRTAS1R3TAS1R1 | |
| SCHEMBL13824190 | 0.81 | KDM4E (0.51) | HTTALDH1A1LMNAKMT2ANPC1 | |
| SCHEMBL13823931 | 0.81 | KDM4E (0.48) | ALDH1A1LMNAKDM4E | |
| SCHEMBL13824116 | 0.80 | KDM4E (0.53) | HTTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL14082169 | 0.79 | HTT (0.71) | HTTALDH1A1TSHRTAS1R3TAS1R1 | |
| SCHEMBL5122846 | 0.78 | TAS1R3 (0.46) | HTTALDH1A1TSHRTAS1R3TAS1R1 | |
| SCHEMBL13729216 | 0.77 | TAS1R3 (0.47) | ALDH1A1TSHRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13728247 | 0.77 | RAB9A (0.46) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL29563786 | 0.76 | HTT (0.65) | HTTALDH1A1TSHRTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ADA, TYMP, ITPA | HTT 1701/4885ALDH1A1 1277/4885TSHR 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.